Search results
Added:
2 months ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Nadira Hamid
Research Area(s) / Expertise:
Job title: Cardiologist & Director of the Echocardiography Core Laboratory
Author
Joseph C Cleveland Jr
Research Area(s) / Expertise:
Author
Expertise
View from the Thoraxcenter: What's Hot at AHA 24?
Added:
1 year ago
Podcast Episode
William H Sauer
Research Area(s) / Expertise:
Author
Expertise
Added:
2 months ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England…
View more
Cardiovascular Manifestations in Post-COVID-19 Patients
Author(s):
Angela Cozma
,
Violeta Briciu
,
Adela Viviana Sitar-Tăut
,
et al
Added:
1 year ago
Original Research
Michael S Firstenberg
Research Area(s) / Expertise:
Author
Expertise
Jeroen J Bax
Research Area(s) / Expertise:
Author